IBDEI1M3 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,417,0)
 ;;=WOMEN'S HEALTH^51^39
 ;;^UTILITY(U,$J,358.4,418,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^52^39
 ;;^UTILITY(U,$J,358.4,419,0)
 ;;=COMA^20^39
 ;;^UTILITY(U,$J,358.4,420,0)
 ;;=CAUSES OF INJURY^19^39
 ;;^UTILITY(U,$J,358.4,421,0)
 ;;=DEMENTIA^21^39
 ;;^UTILITY(U,$J,358.4,422,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^37^39
 ;;^UTILITY(U,$J,358.4,423,0)
 ;;=ACQUIRED ABSENCE OF BODY PART(S)^2^39
 ;;^UTILITY(U,$J,358.4,424,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^49^39
 ;;^UTILITY(U,$J,358.4,425,0)
 ;;=ACSC ACUTE KIDNEY FAILURE^3^39
 ;;^UTILITY(U,$J,358.4,426,0)
 ;;=ACSC ANGINA^4^39
 ;;^UTILITY(U,$J,358.4,427,0)
 ;;=ACSC ASTHMA/BRONCHITIS/COPD^5^39
 ;;^UTILITY(U,$J,358.4,428,0)
 ;;=ACSC CHF^6^39
 ;;^UTILITY(U,$J,358.4,429,0)
 ;;=ACSC DEHYDRATION^7^39
 ;;^UTILITY(U,$J,358.4,430,0)
 ;;=ACSC DIABETES TYPE 1^8^39
 ;;^UTILITY(U,$J,358.4,431,0)
 ;;=ACSC DIABETES TYPE 2^9^39
 ;;^UTILITY(U,$J,358.4,432,0)
 ;;=ACSC HYPERTENSION^10^39
 ;;^UTILITY(U,$J,358.4,433,0)
 ;;=ACSC INFECTIOUS GASTROENTERITIS^11^39
 ;;^UTILITY(U,$J,358.4,434,0)
 ;;=ACSC PNEUMONIA^12^39
 ;;^UTILITY(U,$J,358.4,435,0)
 ;;=ACSC UTI^13^39
 ;;^UTILITY(U,$J,358.4,436,0)
 ;;=ACSC VIRAL ENTERITIS^14^39
 ;;^UTILITY(U,$J,358.4,437,0)
 ;;=E-CIG/VAPE LUNG INJURY^23^39
 ;;^UTILITY(U,$J,358.4,438,0)
 ;;=TEAM CONFERENCE^20^40
 ;;^UTILITY(U,$J,358.4,439,0)
 ;;=PROCEDURE CODE^15^40
 ;;^UTILITY(U,$J,358.4,440,0)
 ;;=EDUCATION/TRAINING^6^40
 ;;^UTILITY(U,$J,358.4,441,0)
 ;;=IMMUNIZATIONS^9^40
 ;;^UTILITY(U,$J,358.4,442,0)
 ;;=OTH PREVENTIVE MEDICINE SVCS^10^40
 ;;^UTILITY(U,$J,358.4,443,0)
 ;;=SKIN TEST^18^40
 ;;^UTILITY(U,$J,358.4,444,0)
 ;;=PREVENTIVE MED-EST PT^12^40
 ;;^UTILITY(U,$J,358.4,445,0)
 ;;=PREVENTIVE MED-NEW PT^13^40
 ;;^UTILITY(U,$J,358.4,446,0)
 ;;=ADVANCED CARE PLANNING^1^40
 ;;^UTILITY(U,$J,358.4,447,0)
 ;;=IMMUNIZATION ADMINISTRATION^8^40
 ;;^UTILITY(U,$J,358.4,448,0)
 ;;=PHYSICIAN CARE PLAN OVERSIGHT^11^40
 ;;^UTILITY(U,$J,358.4,449,0)
 ;;=COVID-19 RELATED^5^40
 ;;^UTILITY(U,$J,358.4,450,0)
 ;;=CHRONIC CARE MANAGEMENT SERVICES^4^40
 ;;^UTILITY(U,$J,358.4,451,0)
 ;;=ANNUAL WELLNESS W/ PREV PLAN OF SVC^3^40
 ;;^UTILITY(U,$J,358.4,452,0)
 ;;=PROLONGED E&M SVC^16^40
 ;;^UTILITY(U,$J,358.4,453,0)
 ;;=PROLONGED SVC W/O DIRECT PT CONTACT^17^40
 ;;^UTILITY(U,$J,358.4,454,0)
 ;;=HOME HEALTH SUPERVISION^7^40
 ;;^UTILITY(U,$J,358.4,455,0)
 ;;=SMOKING/TOBACCO USE CESSATION COUNSELING^19^40
 ;;^UTILITY(U,$J,358.4,456,0)
 ;;=ALCOHOL/SUBSTANCE ABUSE SCRN/INTVN^2^40
 ;;^UTILITY(U,$J,358.4,457,0)
 ;;=PRINCIPLE CARE MANAGEMENT^14^40
 ;;^UTILITY(U,$J,358.4,458,0)
 ;;=PSYCHIATRIC THERAPY-INDIVIDUAL^8^41
 ;;^UTILITY(U,$J,358.4,459,0)
 ;;=INTAKE/SCREENING^4^41
 ;;^UTILITY(U,$J,358.4,460,0)
 ;;=CASE MANAGEMENT SERVICES^1^41
 ;;^UTILITY(U,$J,358.4,461,0)
 ;;=HEALTH AND BEHAVIOR ASSESSMENT^3^41
 ;;^UTILITY(U,$J,358.4,462,0)
 ;;=EDUCATION/TRAINING^2^41
 ;;^UTILITY(U,$J,358.4,463,0)
 ;;=TEAM CONFERENCE-FTF W/ PATIENT^10^41
 ;;^UTILITY(U,$J,358.4,464,0)
 ;;=MD/PA/NP PSYCHOTHERAPY W/ E&M^6^41
 ;;^UTILITY(U,$J,358.4,465,0)
 ;;=MD/PA/NP/SW PROLONGED SERVICES^5^41
 ;;^UTILITY(U,$J,358.4,466,0)
 ;;=PSYCHIATRIC THERAPY-GROUP^9^41
 ;;^UTILITY(U,$J,358.4,467,0)
 ;;=TEAM CONFERENCE-FTF W/O PATIENT^11^41
 ;;^UTILITY(U,$J,358.4,468,0)
 ;;=PEER SUPPORT^7^41
 ;;^UTILITY(U,$J,358.4,469,0)
 ;;=ABUSE,NEGLECT, & VIOLENCE^1^42
 ;;^UTILITY(U,$J,358.4,470,0)
 ;;=ANXIETY DISORDERS^3^42
 ;;^UTILITY(U,$J,358.4,471,0)
 ;;=BIPOLAR DISORDERS^4^42
